Neuropace Stock News

EPS estimates get slashed 50% but sales still expected to grow for this innovative epilepsy device

NPCE earnings call for the period ending December 31, 2021.

NeuroPace press release (NPCE): Q4 GAAP EPS of -$0.44 misses by $0.10.Revenue of $11M (+2.3% Y/Y) misses by $0.02M.

MOUNTAIN VIEW, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today reported financial results for the fourth quarter and full year ended December 31, 2021.

MOUNTAIN VIEW, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today reported financial results for the fourth quarter and full year ended December 31, 2021.

NeuroPace, Inc. (NPCE) CEO Mike Favet on Q4 2021 Results - Earnings Call Transcript

MOUNTAIN VIEW, Calif., Jan. 27, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy,

NeuroPace <> expects prelim. Q4 unaudited revenue of ~$11M, up 2% from $10.8M in Q4 2020. Prelim

MOUNTAIN VIEW, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ: NPCE ), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today announced its preliminary, unaudited revenue for the fourth quarter and full-year ended December 31, 2021. Based on available financial information, preliminary unaudited fourth quarter 2021 revenue is expected to be approximately $11.0 million, compared to $10.8 million in the fourth quarter in the prior year period, reflecting growth of 2%. Initial implant revenue for the fourth quarter 2021 is expected to be approximately $8.5 million, compared to $7.7 million in the fourth quarter 2020, reflecting growth of 10%. Replacement implant revenue for the fourth quarter 2021 is expected to be approximately $2.5 million, compared to $3.1 million in the fourth quarter 2020, reflecting a decline of 19%. Based on available financial information, preliminary unaudited full-year 2021 revenue is expected to be approximately $45.2 million, compared to $41.1 million in full year 2020, reflecting growth of 10%.

NeuroPace Inc (NPCE) shares closed today 13.2% lower than it did at the end of yesterday. The stock is currently down 0.4% year-to-date, down 59.8% over the past 12 months, and down 59.8% over the past five years. Today, the Dow Jones Industrial Average fell 0.0%, and the S&P 500 fell 0.4%. Trading Activity Shares traded as high as $11.82 and as low as $9.71 this week.Shares closed 63.3% below its 52-week high and 21.1% above its 52-week low.Trading volume this week was 67.4% lower than the 10-day average and 41.3% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -95.4% The company's stock price performance over the past 12 months lags the peer average by 334.9% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

MOUNTAIN VIEW, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today announced that Mike Favet, CEO, Rebecca Kuhn, CFO and VP of Finance and Administration, and Irina Ridley, General Counsel and Corporate Secretary will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12th, 2022, at 8:15 am Pacific Time / 11:15am Eastern Time.

MOUNTAIN VIEW, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy,

Gainers Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) shares jumped 80.4% to close at $90.08 on Monday. Pfizer agreed to acquire Arena Pharmaceuticals for $100 per share in an all-cash transaction. Foghorn Therapeutics Inc. (NASDAQ: FHTX ) shares jumped 55% to close at $18.58. Loxo Oncology, an R&D group of Eli Lilly And Co (NYSE: LLY ), and Foghorn Therapeutics collaborated to create oncology medicines by applying Foghorn''s Gene Traffic Control platform. BELLUS Health Inc. (NASDAQ: BLU ) gained 48.2% to settle at $8.30 after the company announced topline data its Phase 2b SOOTHE trial of BLU-5937 in Refractory Chronic Cough. Petros Pharmaceuticals, Inc. (NASDAQ: PTPI ) surged 47.4% to close at $3.98 after gaining more than 14% on Friday. Energy Focus, Inc. (NASDAQ: EFOI ) gained 36.2% to close at $4.70. East Stone Acquisition Corporation (NASDAQ: ESSC ) jumped 31.4% to close at $18.40 after gaining over 8% on Friday. Puxin Limited (NYSE: NEW ) climbed 27.1% to settle at $0.41 after tumbling over 10% on Friday.